Related references
Note: Only part of the references are listed.Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
Mark C. Petrie et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study
Insa M. Schmidt et al.
CLINICAL KIDNEY JOURNAL (2019)
Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing
Jiahua Li et al.
CLINICAL KIDNEY JOURNAL (2019)
The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: Keeping chronic kidney disease out of sight of health authorities will only magnify the problem
Alberto Ortiz et al.
NEFROLOGIA (2019)
International comparison of trends in patients commencing renal replacement therapy by primary renal disease
Vianda S. Stel et al.
NEPHROLOGY (2019)
Effect of sodium-glucose cotransporter 2 inhibitor on proximal tubular function and injury in patients with type 2 diabetes: a randomized controlled trial
Bancha Satirapoj et al.
CLINICAL KIDNEY JOURNAL (2019)
The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2016: a summary
Anneke Kramer et al.
CLINICAL KIDNEY JOURNAL (2019)
Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
Beatriz Fernandez-Fernandez et al.
CLINICAL KIDNEY JOURNAL (2019)
Sodium-glucose cotransporter inhibitors: beyond glycaemic control
Ander Vergara et al.
CLINICAL KIDNEY JOURNAL (2019)
Novel Urinary Biomarkers For Improved Prediction Of Progressive Egfr Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease
Maria E. Rodriguez-Ortiz et al.
SCIENTIFIC REPORTS (2018)
Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories
Kyle J. Foreman et al.
LANCET (2018)
Medication discrepancies in late-stage chronic kidney disease
Jamil Ibrahim et al.
CLINICAL KIDNEY JOURNAL (2018)
Clinical and pathological characteristics of non-diabetic renal disease in type 2 diabetes patients
Kittrawee Kritmetapak et al.
CLINICAL KIDNEY JOURNAL (2018)
The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary
Anneke Kramer et al.
CLINICAL KIDNEY JOURNAL (2018)
Women and renal replacement therapy in Europe: lower incidence, equal access to transplantation, longer survival than men
Raul Fernandez-Prado et al.
CLINICAL KIDNEY JOURNAL (2018)
Renal function at the time of nephrology referral but not dialysis initiation as a risk for death in patients with diabetes mellitus
Cedric Pinier et al.
CLINICAL KIDNEY JOURNAL (2018)
Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease
Claudia Pontillo et al.
CLINICAL KIDNEY JOURNAL (2017)
Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes
Esteban Porrini et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in spain: the MERENA observational cohort study
Alberto Martinez-Castelao et al.
BMC NEPHROLOGY (2011)
Share Paper
